Dr. Juan Camilo Arjona Ferreira - 07 Nov 2025 Form 4 Insider Report for Organon & Co. (OGN)

Role
Head of R&D & CMO
Signature
/s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira
Issuer symbol
OGN
Transactions as of
07 Nov 2025
Net transactions value
-$15,480
Form type
4
Filing time
10 Nov 2025, 16:14:08 UTC
Previous filing
12 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Arjona Ferreira Juan Camilo Head of R&D & CMO C/O ORGANON &CO., 30 HUDSON STREET, FLOOR 33, JERSEY CITY /s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira 10 Nov 2025 0001714080

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise $0 +6,446 +26% $0.000000 31,223 07 Nov 2025 Direct
transaction OGN Common Stock Tax liability $15,480 -2,307 -7.4% $6.71 28,916 07 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Options Exercise $0 -6,446 -50% $0.000000 6,447 07 Nov 2025 Common Stock 6,446 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.
F2 These restricted stock units vest and are distributed as shares of Organon common stock in three installments: 6,446 shares on November 7 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026.